GeneTex recombinant antibodies

Thursday, 03 June, 2021 | Supplied by: Sapphire Bioscience

A recombinant antibody (rAb) is generated from the cloned, in vitro-expressed heavy and light chains of a selected monoclonal antibody obtained through classical hybridoma methodology, display strategies alone or in combination, sorted single B cells from immunised animals, or by one of many other techniques. The fact that it is cloned means the rAb is defined by its primary sequence, which can be engineered to optimise affinity and be expressed in different binder formats. The numerous advantages of rAbs have been well documented, with consistency of performance being of particular significance.

GeneTex offers over 300 recombinant antibodies for research into SARS-CoV-2, apoptosis, immune checkpoints, cytoskeleton, JNK signalling and more. The rAb protocol that GeneTex employs is a multi-parameter FACS-based approach to isolate antigen-specific IgG+ memory B cells from an immunised animal, with subsequent cloning of the antibody variable-region genes into an IgG backbone and expression in mammalian cells. This protocol is rapid and can be completed in weeks, thus providing more opportunities to identify antibodies with diverse capabilities in various applications. Importantly, it allows cloning of the heavy and light chains from the same B cell, thereby preserving natural pairing. Once cloned, the supply of a given rAb is inexhaustible.

The company’s recombinant antibodies are renewable, offer high reproducibility and consistency, provide high affinity and specificity, and display a low background signal.

Phone: 02 9698 2022
Related Products

GenScript COVID-19 virus antigens and antibodies

GenScript has developed a comprehensive range of products that scientists may use to accelerate...

ProSci single-domain antibodies

ProSci's sdAb products are designed to introduce a further capability to research regimens in...

GeneTex zebrafish antibodies

The antibodies have been tested on zebrafish samples in a variety of applications including, but...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd